1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: NICOTROL Inhaler
Trade Name: NICOTROL
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against
Intended Use: Pharmaceutical product used as an aid to smoking cessation for the relief of nicotine withdrawal symptoms

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300
Emergency telephone number: International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture
GHS - Classification: Not classified as hazardous

Label Elements

Signal Word: Not Classified
Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
</table>

PZ00532
3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>NICOTINE</td>
<td>54-11-5</td>
<td>200-193-3</td>
<td>Acute Tox. 3 (H301) Acute Tox.1 (H310) Aquatic Chronic 2 (H411)</td>
<td>&lt; 2</td>
</tr>
<tr>
<td>L-Menthol</td>
<td>2216-51-5</td>
<td>218-690-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as mists) may fuel fires/explosions.

Advice for Fire-Fighters
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.
6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Refer to Section 12 - Ecological Information, for information on potential effects on the environment. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical product used as an aid to smoking cessation for the relief of nicotine withdrawal symptoms

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

NICOTINE

ACGIH Threshold Limit Value (TWA) 0.5 mg/m³
ACGIH - Skin Absorption Designation Skin - potential significant contribution to overall exposure by the cutaneous route

Australia TWA 0.5 mg/m³
Austria OEL - MAKs 0.07 ppm 0.5 mg/m³
Belgium OEL - TWA 0.5 mg/m³
Bulgaria OEL - TWA 0.5 mg/m³
Cyprus OEL - TWA 0.5 mg/m³
Czech Republic OEL - TWA 0.5 mg/m³
Denmark OEL - TWA 0.5 mg/m³
Estonia OEL - TWA 0.5 mg/m³
Finland OEL - TWA 0.5 mg/m³
France OEL - TWA 0.5 mg/m³
Germany - TRGS 900 - TWAs 0.05 mg/m³
Greece OEL - TWA 0.5 mg/m³
Hungary OEL - TWA 0.5 mg/m³
Ireland OEL - TWAs 0.5 mg/m³
Italy OEL - TWA 0.5 mg/m³
Latvia OEL - TWA 0.5 mg/m³
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures.

Personal Protective Equipment:

Hands: Wear impervious gloves if skin contact is possible.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Wear protective clothing when working with large quantities.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Oily liquid

Odor: No data available.

Molecular Formula: Mixture

Color: Clear to light yellow

Odor Threshold: No data available.

Molecular Weight: Mixture

Solvent Solubility: No data available

Water Solubility: No data available

pH: No data available.

Melting/Freezing Point (°C): No data available

Boiling Point (°C): No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

L-Menthol

No data available

NICOTINE

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available
10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual ingredients.
Short Term: May cause nervous system and cardiovascular system effects. May be absorbed through the skin and cause systemic effects.
Known Clinical Effects: Clinical use of this drug has caused headache, gastrointestinal disturbances, nausea vomiting, sore throat, sore mouth, changes in heart rate.

Acute Toxicity: (Species, Route, End Point, Dose)

**L-Menthol**
Rat Oral LD50 3300 mg/kg

**NICOTINE**
Rat Oral LD 50 50 - 300 mg/kg
Rat Dermal LD 50 < 50mg/kg
Mouse Oral LD 50 3.34 mg/kg
Mouse Intravenous LD 50 300ug/kg

Irritation / Sensitization: (Study Type, Species, Severity)

**L-Menthol**
Eye Irritation Rabbit Severe
Skin Irritation Rabbit Non-irritating

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

**NICOTINE**
Embryo / Fetal Development Rat 25 mg/kg LOAEL Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

**NICOTINE**
Bacterial Mutagenicity (Ames) Salmonella Negative
11. TOXICOLOGICAL INFORMATION

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Releases to the environment should be avoided. This formulation has not been tested as a whole, the following apply to component substance(s):

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

L-Menthol
*Pimephales promelas* (Fathead Minnow) LC50 96 Hours 18.9 mg/L

**NICOTINE**

*Daphnia magna* (Water Flea) EC50 48 Hours 0.24 mg/L

*Oncorhynchus mykiss* (Rainbow Trout) LC50 96 Hours 4 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

**NICOTINE**

RCRA - P Series Wastes Listed

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

L-Menthol

CERCLA/SARA 313 Emission reporting  Not Listed
California Proposition 65  Not Listed
Inventory - United States TSCA - Sect. 8(b)  Present
Australia (AICS):  Present
EU EINECS/ELINCS List  218-690-9

NICOTINE

CERCLA/SARA 313 Emission reporting  1.0 %
CERCLA/SARA Hazardous Substances and their Reportable Quantities:  100 lb
45.4 kg
CERCLA/SARA - Section 302 Extremely Hazardous TPQs  100 lb
CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs  100 lb
California Proposition 65  developmental toxicity initial date 4/1/90
Inventory - United States TSCA - Sect. 8(b)  Present
Australia (AICS):  Present
Standard for the Uniform Scheduling for Drugs and Poisons:  Schedule 4
Schedule 6
Schedule 7
EU EINECS/ELINCS List  200-193-3

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed
Acute toxicity, dermal-Cat.1; H310 - Fatal in contact with skin
Hazardous to the aquatic environment, chronic toxicity-Cat.2; H411 - Toxic to aquatic life with long lasting effects

Data Sources:  Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision:  Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 16 - Other Information.

Revision date:  07-Mar-2016

Prepared by:  Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.